In Vitro Topoisomerase II Inhibitory and Apoptotic Activities of Novel 3,5 Disubstituted Thiophene-2-carboxylates

Ananda Hanumappa1, Kothanahally S. Sharath Kumar1, Mahesh Hegde1, Kereyagalahally H.Narasimhamurthy1, Sathees C. Raghavan1 and Kanchugarakoppal S Rangappa*

1Department of Studies in Chemistry, University of Mysore, India
2Department of Biochemistry, Indian Institute of Science, India

Submission: April 5, 2016; Published: May 5, 2016

*Corresponding author: Kanchugarakoppal S Rangappa, Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore, 570006, India, Tel: +91-821-2419661; Email: rangappaks@gmail.com

Abstract

Topoisomerases (topoII) are crucial enzymes involved during DNA replication, repair and transcription. Recent studies have shown topo II as an interesting target for cancer therapy. In the current study we have synthesized and characterized few thiophene derivatives and determined their antiproliferative activity and apoptosis studies in cancer cell lines. Biochemical analysis showed that thiophene derivatives inhibit the alpha isoforms of topoisomerase II and hence these molecules can be considered as a potential anticancer drug.

Keywords: Thiophene-2-carboxylates; Aldol condensation; Topoisomerase II; Nalm6 cells; Cytotoxicity

Introduction

Thiophene derivatives represent an important class of sulfur containing heterocycles that is present in numerous bioactive natural products and pharmaceutically active agents [1,2]. Thiophene derivatives are well explored as cytotoxic agents and recognized as a promising topoisomerase I inhibitor [3,4]. From the literature survey, one may presume that thiophene derivatives can bind to various DNA structures and therefore may interfere with DNA associated enzymes. Topoisomerase are considered as one of the important targets for thiophene derivatives. Cancer cells are highly metabolically active due to their proliferative nature. Each time when a cell replicate first replication of DNA takesplace and for which role of topoisomerases is very important [5]. In eukaryotes, Topoisomerase II enzyme (Topo II) is highly over expressed in robustly dividing tumor cells, and plays an important role in DNA replication, nuclear genome maintenance and transcription [6-8]. Hence, this nuclear enzyme is an attractive target for cancer chemotherapy. Nearly 50% of all cancer therapeutics contains at least one entity targeted to htopo II [9-11]. All the topoisomerase II (topo II) -targeted anticancer drugs are clinically used for their antitumor properties. Broad range of topoll inhibitors are normally classified as topo II poisons and catalytic inhibitors [12]. Topoisomerase inhibitors have played a significant role in chemotherapy. The most extensively used topoisomerase II inhibitors include etoposide, doxorubicin, daunorubicin, mitoxantrone, teniposide and amsacrine. However, it is observed that unfortunately, treatment with some of the topo II inhibitors failed after early effective therapy. Therefore, there is need for the development of novel topoisomerase II targeted drugs, with the goal of disabling current boundaries.

Results and Discussion

Chemistry

One of the important synthetic approaches for the preparation of substituted thiophene derivatives is from using functionalized polarized ketene dithioacetals as precursors [13]. However, most of the reported methods suffer from one or the other disadvantages, mainly formation of mixed alkylation products during one pot sequential alkylation with different alkyl halides. Later, selective sequential alkylation has been achieved by Asokan et al. [14], but this method is limited to introduce only alkyl thio group in the 2-position of the thiophene derivatives. Further, Ila et al. [15] have developed sequential one-pot three component route to tri- & tetra substituted/annulated thiophenes, this method produced comparatively low yields of thiophenes. In continuation of our synthetic efforts [16], we set out to identify the possible mild conditions under which, the intermediate β-alkyl thienone would undergo intramolecular aldol condensation with synthetically useful rate. Initially we have started the synthesis of ethyl 3,5-disubstituted thiophene-2-carboxylate derivatives starting directly from 1,3-monothio-
β-diketones in one pot operation. The monothio-β-diketone $3a$ was selected as a model substrate for optimizing the reaction condition for the formation of thiophene $TH1$ in the presence of various bases. Sodium hydroxide in benzene: water (2:1) system with TBAB as a phase transfer catalyst at room temperature was found to be better reaction condition for the synthesis of $TH1$ with 92% yield. With the optimized protocol in hand we went on to synthesize different thiophene derivatives ($TH2$-$TH5$). Thus the 1,3-monothio-β-diketones bearing electron donating and electron withdrawing substituents have also gave the considerable product yield. The probable mechanism for the formation of thiophene looks to be simple, treatment of 1,3-monothio-β-diketones with ethyl bromo acetate in-situ generates β-alkyl thioenone intermediate which underwent in-situ intramolecular aldol condensation to afford ethyl 3,5-disubstituted thiophene-2-carboxylate derivatives in good yield (Table 1) (Scheme 1).

![Scheme 1: Synthetic route to tri substituted thiophene derivatives.](image)

**Table 1: Step-wise synthesis of Ethyl 3,5-disubstituted thiophene-2-carboxylates $TH1$-$5$.**

| Entry | Acetophenone | Dithioester | Product | Yield (%) |
|-------|--------------|-------------|---------|-----------|
| 1     | ![acetophenone](image) | ![dithioester](image) | $TH1$ | 92        |
| 2     | ![acetophenone](image) | ![dithioester](image) | $TH2$ | 86        |
| 3     | ![acetophenone](image) | ![dithioester](image) | $TH3$ | 89        |
| 4     | ![acetophenone](image) | ![dithioester](image) | $TH4$ | 90        |
| 5     | ![acetophenone](image) | ![dithioester](image) | $TH5$ | 85        |

**Biological studies**

**Effect of $TH1$ on various human cancer cell lines:** The activity of newly synthesized thiophene compounds were checked in various human cancer cell lines such as Molt4, Nalm6, K562 and HEK 293T for their cytotoxic activity. The MTT assay results confirmed that the tested compounds inhibit the cell proliferation after 48h at different concentrations. Importantly, $TH1$ inhibited the growth of Molt4, Nalm6 and K562 cells in dose dependent manner with $IC_{50}$ value of 68.9, 69.2 and 82.1µM respectively. Furthermore $TH1$ didn’t inhibit the growth of normal cells such as Human epithelial kidney (HEK293T) cells with $IC50$ value of 141.2µM. These results suggested that $TH1$ inhibits the growth of human cancer cells.

**$TH1$ causes the accumulation of the cells in the SubG1 phase of the cell cycle in human leukemic cells:** In order to assess the influence of $TH1$ on cell cycle, Nalm6 cells were treated with $TH1$ and examined the effect after 48h treatment of $TH1$ (25, 50, 75 & 100 µM) on Nalm6 cells induced concentration dependent increase in SubG1 population of cell cycle and it was prominent at 100µM. This data indicated that $TH1$ could promote cell death through apoptosis without affecting to cell cycle arrest. The bar graph representing different stages of cell population (Figure 1A&1B) of $TH1$ treated cells appeared to induce cell death in concentration dependent manner in Nalm6 cells.

**Live dead assay for $TH1$ on Nalm6 cells:** We carried out live dead cell assay using calcein and propidium iodide staining to confirm the cell death induced by $TH1$ on Nalm6 cells. Calcein stains live cells and propidium iodide stains only dead cells because of the damaged cell membrane. The 48 h treatment of $TH1$ showed increase in propidium iodide stained (single and double positive) cells in a dose dependent manner (50, 75 and 100 µM) and decreased number of calcein-AM stained cells.
which further confirming the cytotoxic effect caused by TH1 on Nalm6 cells (Figure 2A & 2B).

**Study of mitochondrial membrane potential assay:**

Study of mitochondrial membrane potential (Δψm) is an important parameter in anti-cancer drug discovery pipeline. We evaluated the effect of TH1 on mitochondrial membrane potential in Nalm6 cells using JC-1 (5,5′, 6, 6′-tetrachloro-1, 1′, 3, 3′-tetraethylbenzimidazol -carbocyanineiodide) dye. In normal mitochondria JC-1 forms aggregate and emits red fluorescence, on the other hand the dead population with low mitochondrial membrane potential dye remains in monomeric form which emits green fluorescence. Interestingly, 48h of TH1 treatment (75 and 100 µM) lead decrease in the mitochondrial membrane potential in Nalm6 cells which was evident in the increased green fluorescence (Figure 3A&3B). This suggested that participation of mitochondrial apoptotic mechanism in induction of cell death upon treatment with TH1 in Nalm6 cells.

**Action of TH1 leads to induction of apoptosis:** The increase in subG1 population and cell death which were evident in cell cycle analysis and live dead assay induced by TH1 on Nalm6 cells lead us to detect the mode of the cell death induced by TH1. Hence we stained the Nalm6 cells which are treated with TH1 (48h, 75 µM) with annexin-FITC and propidium iodide to study the different types of apoptotic cell populations. The externalization of phosphatidylserine (PS) in living cells is a hallmark of apoptosis. Soon after apoptosis is induced, PS is translocated from the inner leaflet of the plasma membrane to the outer leaflet. We observed increase of early, late apoptotic cells (8.1%, 24.7%) at 75µM compared to DMSO treated control (5.7%, 3.6%) respectively (Figure 4A&4B). Results revealed that the Compound TH1 induced cell death in Nalm6 cells by inducing apoptosis.

**Inhibition of human DNA topoisomerase II:** It was evident that TH1 is the active potent compound in tested panel in ex vivo studies. While additional studies are necessary to develop a further understanding on mechanism of action of the TH1 compound. Majority of pharmacological agents bind to DNA and exhibit their effect through interference with the activity of topoisomerase [17,18]. The interaction with cellular macromolecules is the basis for the selective anticancer activity for any class of heterocyclic compounds. Thiophene derivatives are one among them which demonstrated drugs selective cytotoxicity and caused severe disturbance of the cell cycle and inhibited topoisomerases which related to DNA binding activity. Hence, we performed topoisomerase assay using human topoisomerase II. Furthermore we analyzed the effect of TH1 on human topoisomerase II alpha mediated relaxation assay. TH1 compound showed significant inhibition of topoisomerase II alpha activity from 50 µM onwards. VP16 (Topo II inhibitor) were used as positive control (Figure 5). Our results showed that inhibitory activities of topoisomerase II enzyme.
Conclusion

In summary, we report step-wise synthesis and biological evaluation of new thiophene derivatives. Among synthesized molecules TH1 showed enhanced cytotoxicity in leukemia cell lines. Preliminary results about mechanism of action of compound suggested that it is having better capacity to induce apoptosis and substantial effect on topoisomerase II activity. All these revealed that significant correlation in the cytotoxicity. All of these above mentioned considerations tempted us to identify the capability of thiophene-2-carboxylates of generating DNA interactive species that lead to their anticancer activity.

Experimental Section

Reactions were monitored by TLC using precoated sheets of silica gel G/UV-254 of 0.25 mm thickness (Merck 60F254) using UV light for visualization. The melting points were determined on Shimadzu FT-IR model 8300 spectrophotometer.

Ethyl 3,5-disubstituted thiophene-2-carboxylate (TH1-5)

Monothio-β-diketones (3a-e) were synthesized by the reaction between different acetonophenes (1a-e) with dithioesters (2a-c) [19,20]. To a stirred solution of monothio-β-diketones 3a-e (1.0 mmol), 10% aq. Na OH (2.0 m l) and TBAB (catalytic) in benzene (10 volume), ethylbromoacetate (1.0 mol) was added drop wise at 0°C. The reaction mixture was kept at 0°C for 12 hours. 10% aq. NaOH (2.0 m mol) and TBAB (catalytic) in benzene (10 volume), ethylbromoacetate (1.0 mol) was added drop wise at 0°C. The reaction mixture was kept at 0°C for 12 hours.

was evaporated under reduced pressure to get a crude product which was purified by silica gel column chromatography using hexane ethylacetate as eluent to get pure product.

**Ethyl 3,5-diphenylthiophene-2-carboxylate (TH1)**

Off white solid (92%): mp 67-69 °C; RF 0.5 (2:8 EtOAc : Hexane); IR (KBr, cm⁻¹) 2976, 1668, 1602, 1462, 1435, 1365, 1269, 1131, 819, 764, 657, 501; ¹H NMR (400 MHz, CDCl₃) δ 7.67-7.65 (d, J = 7.2 Hz, 2H, ArH), 7.51-7.48 (m, 2H, Ar H), 7.44-7.36 (m, 6H, ArH), 7.29 (s, 1H, C₆H), 4.27-4.22 (q, J = 7.2 Hz, 2H, OCH₂CH₃), 1.27-1.23 (t, J = 7.2 Hz, 3H, OCH₃), 13C NMR (100 MHz, CDCl₃) δ 161.0, 135.3, 135.2, 133.4, 131.0, 129.8, 129.0, 127.9, 127.3, 127.0, 124.7, 121.5, 119.9, 60.3, 14.1; HRMS (ESI) m/z Calcd for C₂₀H₁₈O₂S [M + Na]+ 331.0871, found 331.0895.

**Ethyl3-(3,4-dimethoxyphenyl)-3-(4-(trifluoromethyl)phenyl)thiophene-2-carboxylate (TH2)**

Pale yellow solid (86%): mp 108-110 °C; RF 0.35 (2:8 EtOAc : Hexane); IR (KBr, cm⁻¹) 2987, 2849, 1667, 1627, 1611, 1299, 1152, 1098, 845, 739, 634, 538; ¹H NMR (400 MHz, CDCl₃) δ 7.66-7.64 (d, J = 8.0 Hz, 2H, ArH), 7.60-7.58 (d, J = 8.0 Hz, 2H, ArH), 7.24 (s, 1H, C₆H), 7.114-7.110 (d, J = 1.6 Hz, 2H, ArH), 6.90-6.88 (d, J = 8.0 Hz, 1H, ArH), 4.42-4.40 (q, J = 8.0 Hz, 2H, OCH₂CH₃), 3.93 (s, 3H, OCH₃), 3.91 (s, 3H, OCH₃), 1.26-1.22 (t, J = 7.0 Hz, 3H, OCH₂CH₃), 13C NMR (100 MHz, CDCl₃) δ 160.2, 149.0, 132.8, 132.8, 129.0, 127.9, 127.8, 125.7, 125.19, 125.15, 125.13, 125.11, 122.1, 120.0, 119.7, 109.4, 109.2, 61.5, 55.9, 55.9, 14.0; HRMS (ESI) m/z Calcd for C₂₂H₁₅F₃O₂S [M + Na]+ 459.4444, found 459.0854.

**Ethyl(4-methoxyphenyl)-5-phenylthiophene-2-carboxylate (TH3)**

Off white solid (99%): mp 91-93°C; RF 0.4 (2:8 EtOAc : Hexane); IR (KBr, cm⁻¹) 2978, 2849, 1661, 1603, 1462, 1437, 1365, 1268, 1134, 819, 764, 657, 505; ¹H NMR (400 MHz, CDCl₃) δ 7.65-7.63 (d, J = 8.0 Hz, 2H, ArH), 7.45-7.39 (m, 5H, ArH), 7.25 (s, 1H, C₆H), 6.94-6.92 (d, J = 8.0 Hz, 2H, ArH), 4.27-4.23 (q, J = 7.2 Hz, 2H, OCH₂CH₃), 3.83 (s, 3H, OCH₃), 1.28-1.23 (t, J = 7.2 Hz, 3H, OCH₂CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 160.6, 145.3, 140.0, 133.4, 131.0, 129.5, 129.0, 127.9, 127.6, 127.0, 126.7, 126.5, 121.5, 114.9, 60.8, 55.4, 14.1; HRMS (ESI) m/z Calcd for C₂₀H₁₅O₂S [M + Na]+ 361.0977, found 361.0994.

**Ethyl(4-methoxyphenyl)-5-m-tolylthiophene-2-carboxylate (TH4)**

Yellow solid (90%): mp 97-99°C; RF 0.35 (2:8 EtOAc : Hexane); IR (KBr, cm⁻¹) 2999, 2843, 1674, 1479, 1448, 1297, 1256, 1242, 1019, 802, 729, 533; ¹H NMR (400 MHz, CDCl₃) δ 7.71-7.67 (m, 2H, ArH), 7.61-7.59 (m, 2H, ArH), 7.56-7.54 (d, J = 8.0 Hz, 2H, ArH), 7.24-7.22 (d, J = 8.0 Hz, 2H, ArH), 7.21 (s, 1H, C₆H), 4.27-4.22 (q, J = 7.0 Hz, 2H, OCH₂CH₃), 2.39 (s, 3H, Ar-CH₃), 1.28-1.24 (t, J = 7.2 Hz, 3H, OCH₂CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 161.0, 133.0, 130.5, 129.5, 129.0, 127.9, 127.6, 127.6, 127.0, 126.6, 125.9, 114.9, 60.8, 55.4, 14.1; HRMS (ESI) m/z Calcd for C₂₀H₁₅O₂S [M + Na]+ 361.0977, found 361.0994.
Organic and Medicinal Chemistry International Journal

151.8, 137.4, 135.7, 134.6, 133.9, 130.2, 127.4, 127.5, 126.6, 126.3, 126.0, 121.5, 114.4, 60.2, 55.3, 21.4, 14.1; HRMS (ESI) m/z Calcd for C_{34}H_{32}O_{10}S [M + Na]⁺ 375.1133, found 375.1156.

Ethyl 3-[(furan-2-yl)-5-(4-methoxyphenyl) thiophene-2-carboxylate (TH5)]

Pale yellow solid (85%): mp 101-103°C; RF 0.3 (2:8 EtOAc : Hexane): IR (KBr, cm⁻¹) 2988, 2842, 1671, 1485, 1467, 1278, 1237, 1186, 1029, 784, 521; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (br s, 1H, ArH), 7.60-7.53 (d, J = 8.0 Hz, 2H, ArH), 7.59-7.551 (d, J = 3.2 Hz, 1H, ArH), 7.24 (s, 1H, C₆H), 6.93-6.91 (d, J = 8.0 Hz, 2H, ArH), 6.59-6.55 (d, J = 1.6 Hz, 1H, ArH), 4.36-4.31 (q, J = 8.0 Hz, 2H, OCH₂CH₃), 3.83 (s, 3H, OCH₃), 2.13-2.09 (d, J = 8.0 Hz, 2H, ArH); ¹³C NMR (100 MHz, CDCl₃) δ 151.8, 148.8, 141.0, 135.5, 126.3, 122.9, 116.7, 114.4, 111.5, 109.3, 106.1, 60.5, 55.1, 14.0; HRMS (ESI) m/z Calcd for C_{24}H_{19}O_{5}S [M + Na]⁺ 351.0769, found 351.0812.

Biology

All chemical reagents were obtained from SRL, India, and Sigma-Aldrich, USA. Culture medias were from Sera Laboratory International limited (West Sussex, UK), FBS and Pen Strep were from (Gibco BRL, USA). Topoisomerase IIα enzyme (Topo GEN Inc USA).

Cell lines and culture

Human cell lines, K562, HEK 293T were purchased from National Center for Cell Science, Pune, India. Cells were grown in RPMI 1640, MEM and DMEM supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 U/mL of Penicillin, and 100 µg of streptomycin/mL and incubated at 37°C in a humidified atmosphere containing 5% CO₂. Nalm6 and Molt4 cells were cultured and maintained as described [21]. The cells were grown under the similar culture conditions as mentioned above.

MTT assay

The antiproliferative effect of thiophene derivatives against different cancer cell lines was determined by the MTT dye uptake method as mentioned previously [22,23]. Molt4, Reh, and Nalm6 cells (5 x 10⁴ cells/ml) were treated with different concentration of thiophene derivatives (25, 50, 75 & 100 µM) for 48 h and 100 µl cell suspensions was taken duplicates in a 96 well plate. Thereafter, 20 µl MTT (5 mg/ml in PBS) was added and incubated for 4h at 37°C and the resulting blue crystals were dissolved upon adding 69 µl of lysis buffer (50% final concentration of N, N-dimethylformamide and 10% of sodium dodecyl sulfate, 30 min at 37°C). And subsequently the optical density (OD) was measured at 570 nm using ELISA plate reader.

Cell cycle analysis

The study of DNA substance analysis in cells was performed as mentioned earlier [24]. Nalm6 cells were seeded (0.5x10⁵ cells/ml) and treated with different concentrations of TH1 (25, 50, 75, 100 µM) for 48 h. Cells were harvested, washed and fixed with 80% cold ethanol, and treated with RNase-A (50 µg/ml). Cells were stained with propidium iodide (10µg/ml) and cell cycle progression was monitored using flow cytometer (BD FACSVerse™). A minimum of 10000 cells were acquired. Results were analyzed using Flowing Software (Version 2.5) and plotted histograms.

Live dead cell assay

The live dead cell assay was performed to determine the viability of cells [25]. It is a two color fluorescence assay that simultaneously determines live and dead cells. Live cells have intracellular esterases that convert non fluorescent, cell permeable Calcein acetoxyethyl (Calcein-AM). Dead cells have damaged membranes, the propidium iodide (PI) enters damaged cells and is fluorescent when bound to nucleic acids, PI produces a bright red fluorescence in damaged or dead cells [26]. Cells were treated with different concentrations of TH1 (50, 75 and 100 µM for 48 h). Cells were harvested after processed and finally acquired for live cells the excitation (max) and emission (max) are 480nm and 527/32 nm, respectively and dead cells, the excitation (max) and emission (max) are 480 nm and 586/42 nm, respectively were used (FACS Verse™, BD Biosciences, USA). Results were analyzed in FACSDiva software and presented as dot plot. Quantification of live and dead cells was shown as bar diagram based on two independent experiments.

JC-1 Assay

The study of mitochondrial permeability conversion is an important hallmark for study of apoptosis [27]. To assess the mitochondrial membrane potential, Nalm6 cells were seeded in 12 wellplates (0.5 x 10⁴ cells/ml), treated with TH1 at different concentration (75 and 100 µM). After incubation at 37°C for 48 h, cells were harvested, washed with 1x PBS and stained with (0.5 µg/ml) JC-1 dye for 30 min at 37°C. After incubation, cells were washed and re-suspended in 0.3 ml of 1x PBS and acquired in flow cytometer (FACSVerse™, BD Biosciences, USA) using Cell Quest Pro Software. Minimum of 10,000 cells were acquired per sample and 2, 4-Dinitrophenol (2, 4-DNP) was used as positive control. Data were analyzed using Flowing Software (Version 2.5).

Detection of apoptosis by Annexin V/PI staining

Quantification of apoptotic cells at the single cell level was performed by Annexin V FITC/PI (Santacruz, USA) staining. Cells were seeded in 6 well plates (0.75x10⁴ cells/ml) and treated 75 µM TH1 for 48 h. Cells were harvested and processed according to the manufactures instructions [28]. Briefly, cells were washed with 1x PBS, resuspended in binding buffer (10 m HEPES, 140 mM NaCl, 2.5 mM CaCl₂, pH 7.4) containing annexin V-FITC (0.2 mg/ml) and propidium iodide (0.05 mg/ml), incubated at room temperature for 15 min and analyzed immediately in flow
Topoisomerase II DNA relaxation assay

The topoisomerase II assay was performed in a reaction mixture containing pBS-SK+ plasmid (Sigma Aldrich, USA), two units of recombinant human DNA topoisomerase II (Topo GENInc, USA) along with the various concentrations of test compounds [29]. Reaction was carried out at 37°C for 30 min in a relaxation buffer 1x topo II buffer (50 mM Tris-Cl (pH 8.0), 10 mM NaCl, 10 mM MgCl₂, 5 mM ATP, 0.5 mM dithiothreitol and 30 µg BSA/ml) and reactions were terminated by adding 5x stop buffer containing 5% sarkosyl, 0.0025% bromophenol blue, 25% glycerol. The DNA samples were electrophoresed on 1% agarose gel at 40 volts for 4 h with 0.5x TBE (Tris-borate-EDTA). The gels were stained for 30 min in milli Q water containing ethidium bromide (0.5 mg/ml) followed by destaining for 30 min in milli Q water and images were taken.

Acknowledgment

The authors are grateful to the DST-IFCPR & CSIR Projects, Govt. of India for financial support to K.S.R. for the project vide No.IFC/4303-1/2010-11 Dated 22-12-2010, No. 01 (2434) /10/ EMR-II Dated 28.12.2010. A.H. thanks ICMR for SRF (SRF NO.IFC/4303-1/2010-11 Dated 22-12-2010, No. 01 (2434) Govt. of India for financial support to K.S.R. for the project vide

References

1. Doré K, Dubus S, Ho HA, Lévesque I, Brunette M, et al. (2004) Fluorescent polymeric transducer for the rapid simple and specific detection of nucleic acids at the zeptomole level. J Am Chem Soc 126(13): 4249-4244.
2. Pillai AD, Rathod PD, Xavier FP, Vasu KK, Padh H, et al. (2004) Design synthesis and pharmacological evaluation of some 2-[4-morpholino]-3-aryl-5-substituted thiophenes as novel anti-inflammatory agents generation of a novel anti-inflammatory.pharmaceutical. Bioorganic & Medicinal Chemistry 12(17): 4667-4671.
3. Ilyinsky NS, Shchylkina AK, Borisova OF, Mamaeva OK, Zveeva MI, et al. (2014) Novel multi-targeting anthra[2,3-b] thiophene-5,10-diones synthesize of 1-aryl-3,5-bis(het)arylpyrazoles with complementary 1,3-diketones and 1,3-bis(het)aryl-3-(methylthio)-2-propenones cyclocondensation of arylhydrazines with 1,3-bis(het)arylmonothio-1,3-diketones and 1,3-bis(het)aryl-3-(methylthio)-2-propenones synthesis of 1-aryl-3,5-bis(het)arylpyrazoles with complementary regioselectivity. J Org Chem 79(10): 4960-4973.
4. Basnet A, Thapa P, Karki R, Choi H, Choi JH, et al. (2010) 2 6-Dithienyl 4 furyl pyridinies Synthesis topoisomerase I and II inhibition cytotoxicity structure activity relationship and docking. Bioorg Med Chem Lett 20(1): 42-47.
5. Jiménez-Alonso S, Orellana HC, Estévez-Braun A, Ravelo AG, Pérez-Sacau, et al. (2008) Design and synthesis of a novel series of pyranoanthraquinones as topoisomerase II catalytic inhibitors. J Med Chem 51(21): 6761-6772.
6. Austill CA, Marsh KL (1998) Eukaryotic DNA topoisomerase II beta. Bioessays 20(3): 215-226.
7. Wang JC (2002) Cellular roles of DNA topoisomerases a molecular perspective. Nat Rev Mol Cell Biol 3(6): 430-440.
8. Carpenter AJ, Porter AC (2004) Construction characterization and complementation of a conditional-lethal DNA topoisomerase Ialpha mutant human cell line. Mol Biol Cell 15(12): 5700-5711.
9. Solary E, Bertrand R, Pommier Y (1994) Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymphoma 15(1-2): 21-32.
10. Hammonds TR, Maxwell A, Jenkins JR (1998) Use of a rapid throughput in vivo screen to investigate inhibitors of eukaryotic topoisomerase II enzymes. Antimicrob Agents Chemother 42(4): 889-894.
11. Wilstermann AM, Osheroff N (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 3(3): 321-38.
12. Larsen AK, Escargueil AE, Składanski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99(2): 167-81.
13. Augustin M, Rudorf WD and Schmidt U (1976) Tetrahedron 32: 3055.
14. Samuel R, Chandran P, Retnamma S, Sastikala KA, Sreedevi NK, et al. (2008) Alkylation of 3 ary 3 oxopropenediol and 3 amino 1 aryl 3 thio 1 pyranonaphthoquinones as topoisomerase II catalytic inhibitors. J Med Chem 51(21): 6761-6772.
15. Anand A, Acharaya A, Parameshwarappa G, Saraiya R, Ila H, et al. (2015) Sequential One-Pot Synthesis of Tri- and Tetrasubstituted Thiophenes and Fluorescent Push Pull Thiophene Acrylates Involving (Het)aryl Dithioesters as Thiocarbonyl Precursors. J Org Chem 80(1): 41-427.
16. Narasimhamurthy KH, Chandrappa S, Kumar KSS, Swaroop TS, Rangappa KS, et al. (2013) Chem Lett 42: 1073-1075. (b) Narasimhamurthy KH, Chandrappa S, Karka KSS, Harsha KB, Ananda A, et al. (2014) RSC Adv: 434497. (c) Girish YR, Kumar KSS, Umashankar K, Lokanath NK, Rangappa KS, et al. (2014) RSC Adv: 558600. (d) Kumar KSS, Swaroop TR, Harsha KB, Narasimhamurthy KH, Rangappa KS, et al. (2012) Tetrahedron Lett 53(42): 5619-5625. (e) Girish YR, Kumar KSS, Thimmaiah KN, Rangappa KS, Shashikanth S (2015) RSC Adv 5: 75533-75546.
17. Cai X1, Gray PJ, Von Hoff DD (2009) DNA minor groove binders back in the groove. Cancer Treat Rev 35(5): 437-450.
18. Pendleton K, Lindsey RH, Felix CR, Grimmwa D, Osheroff N, et al. (2014) Topoisomerase II and leukemia. Ann N Y Acad Sci 1310(1): 98-110.
19. Lingaraju GS, Swaroop TR, Vinaayka AC, Kumar KSS, Sadashiva MP, et al. (2012) Synthesis 44: 1373-1379.
20. Kumar SV, Yadav SK, Raghava B, Saraiya B, Rangappa KS, et al. (2013) Cyclodepsination of arylhazdrazines with 1,3-bis(hey)arylimonothio-1,3-diketones and 1,3-bis(hey)aryl-3-(methylthio)-2-propenones synthesis of 1-aryl-3,5-bis(hey)arylpyrazoles with complementary regioselectivity. J Org Chem 79(10): 4960-4973.
21. Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, et al. (2012) An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 151(7): 1474-87.
22. Kumar KSS, Hanumapara A, Vetrivel M, Hegde M, Girish YR, et al. (2015) Antiproliferative and tumor inhibitory studies of 2,3 disubstituted 4-thiazolidinone derivatives. Bio Med Chem Lett 25(17): 3616-3620.
23. Srivastava M, Hegde M, Chiruvella KK, Koroth J, Bhattacharya S, et al. (2014) Sapodilla plum (Achras sapota) induces apoptosis in cancer cell lines and inhibits tumor progression in mice. Sci Rep 21(4): 6147.
24. Kumar KSS, Hanumapara A, Vetrivel M, Hegde M, Girish YR, et al. (2015) Antiproliferative and tumor inhibitory studies of 2,3 disubstituted 4-thiazolidinone derivatives. Bio Med Chem Lett 25(17): 3616-3620.
25. Soland MA, Bego M, Colletti E, Zanjani ED, St Jeor S, et al. (2013) In Vitro Topoisomerase II Inhibitory and Apoptotic Activities of Novel 3,5 Disubstituted Thiophene-2-Carboxyl. Organic & Medicinal Chem IJ. 2016; 1(2): 555556.
Mesenchymal stem cells engineered to inhibit complement-mediated damage. PLoS one 8(3): 60461.

26. Moorby BT, Ravi S, Srivastava S, Chiruvella KK, Hemlal H, et al. (2010) Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bio Med Chem Lett 20(21): 6297-6301.

27. Chiruvella KK, Raghavan SC (2011) A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells. Invest new drugs 29(4): 583-592.

28. Kavitha CV, Nambiar M, Kumar CSA, Choudhary B, Muniyappa K, et al. (2009) Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. Pharmacol 77(3): 348-363.

29. Hegde M, Kumar KSS, Thomas E, Hanumappa A, Rangappa KS, et al. (2015) A novel benzimidazole derivative binds to the DNA minor groove and induces apoptosis in leukemic cells. RSC Adv 5: 93194-93208.